Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NASDAQ: NTLA) from Peerperform to Underperform with a price target of $9.00.The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades